CLRB (Cellectar Biosciences) Total Stockholders Equity: $3.34 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLRB Cellectar Biosciences Inc CLRB
19 GF Score
Price $2.41
! 1 Warning Sign
View Full Analysis

What is Cellectar Biosciences Total Stockholders Equity?

Cellectar Biosciences CLRB -2.82% 19 Total Stockholders Equity is $3.34 Mil as of Mar. 2026. GuruFocus rates CLRB with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

Cellectar Biosciences's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $3.34 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Cellectar Biosciences's Book Value per Share for the quarter that ended in Mar. 2026 was $0.66. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Cellectar Biosciences's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.46.

Cellectar Biosciences  (NAS:CLRB) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Cellectar Biosciences's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(3.335-0.521)/4.240
=0.66

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Cellectar Biosciences's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 1.529) / 3.335
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectar Biosciences Total Stockholders Equity Related Terms

Cellectar Biosciences Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Cellectar Biosciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectar Biosciences Total Stockholders Equity Chart

Cellectar Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.05 8.15 -15.16 14.30 8.54

Cellectar Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.25 6.09 8.00 8.54 3.34
CLRB
19GF Score
Cellectar Biosciences Inc CLRB
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $3.34 Mil mean?
Cellectar Biosciences (CLRB) has a Total Stockholders Equity of $3.34 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Cellectar Biosciences and its competitors.
Is Cellectar Biosciences' Total Stockholders Equity too high?
Cellectar Biosciences' current Total Stockholders Equity is $3.34 Mil. Overall, Cellectar Biosciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Cellectar Biosciences' Total Stockholders Equity compare to OTLC and PTN?
Cellectar Biosciences' Total Stockholders Equity of $3.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Cellectar Biosciences and its competitors. Cellectar Biosciences's current Total Stockholders Equity is $3.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectar Biosciences stock overvalued right now?
Cellectar Biosciences (CLRB) has a current Total Stockholders Equity of $3.34 Mil. The current Total Stockholders Equity is $3.34 Mil. Cellectar Biosciences' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Cellectar Biosciences (CLRB), the current Total Stockholders Equity is $3.34 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cellectar Biosciences Business Description

Address 100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
19GF Score

Get the complete analysis for CLRB

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.41
Price